Switching to a Minimed 780G closed-loop hybrid system: Real-life experience in a center of Latin America
Introduction: Insulin pumps serve as alternative insulin delivery methods with physiological similarity to the normal pancreas. The MiniMed 780G device is an advanced closed-loop hybrid system. Recent real-life studies have allowed reaching a higher percentage of time in range (TIR) (70 to 180 mg/dL...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Endocrine and Metabolic Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266639612300016X |
| _version_ | 1797736823329390592 |
|---|---|
| author | Guillermo Edinson Guzmán-Gómez Karen Milena Feriz-Bonelo Víctor Manuel Blanco-Pico María Angelica Guerra Oriana Arias-Valderrama Valentina Marin-Betancourth Andrés Octavio García-Trujillo |
| author_facet | Guillermo Edinson Guzmán-Gómez Karen Milena Feriz-Bonelo Víctor Manuel Blanco-Pico María Angelica Guerra Oriana Arias-Valderrama Valentina Marin-Betancourth Andrés Octavio García-Trujillo |
| author_sort | Guillermo Edinson Guzmán-Gómez |
| collection | DOAJ |
| description | Introduction: Insulin pumps serve as alternative insulin delivery methods with physiological similarity to the normal pancreas. The MiniMed 780G device is an advanced closed-loop hybrid system. Recent real-life studies have allowed reaching a higher percentage of time in range (TIR) (70 to 180 mg/dL). Being an emerging technology, it is of the utmost value to report on the early experience of use of this device. Methods: This was an observational, descriptive, cross-sectional study that included patients older than 18 years with types 1 diabetes mellitus and other types switched to a Medtronic 780G insulin pump. Baseline clinical and glycemic control variables and those after 4 weeks of using the SmartGuard mode were evaluated. Results: Thirty-nine patients (mean age, 33 years) were analyzed, 95 % of whom had type 1 diabetes with an average disease duration of 17 years. The values for time below range (TBR) <54 mg/dL, TBR <70 mg/dL, TIR, time above range (TAR) >180 mg/dL, and TAR >250 mg/dL were 0 %, 3 %, 72 %, 21 %, and 3 %, respectively, at baseline and 1 %, 2 %, 79 %, 14 %, and 2 %, respectively, after the intervention. The changes in TIR varied based on prior therapy: multiple daily injections of insulin, 13 % improvement; MiniMed Paradigm Veo/MiniMed 640G, 6 % improvement; and MiniMed 670G, −4 % improvement. Conclusion: In conclusion, the application of a hybrid closed-loop system allowed for better glycemic control based on international standards. The average percentage improvement in TIR was lower than that in other studies and was dependent on the previous method of insulin administration, achieving lower performance with the migration from recent technologies such as the Minimed 670G. |
| first_indexed | 2024-03-12T13:19:29Z |
| format | Article |
| id | doaj.art-79db9c6a545b46a19c99a5ff4232cfd7 |
| institution | Directory Open Access Journal |
| issn | 2666-3961 |
| language | English |
| last_indexed | 2024-03-12T13:19:29Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Endocrine and Metabolic Science |
| spelling | doaj.art-79db9c6a545b46a19c99a5ff4232cfd72023-08-26T04:44:15ZengElsevierEndocrine and Metabolic Science2666-39612023-09-0112100139Switching to a Minimed 780G closed-loop hybrid system: Real-life experience in a center of Latin AmericaGuillermo Edinson Guzmán-Gómez0Karen Milena Feriz-Bonelo1Víctor Manuel Blanco-Pico2María Angelica Guerra3Oriana Arias-Valderrama4Valentina Marin-Betancourth5Andrés Octavio García-Trujillo6Universidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, Colombia; Fundación Valle del Lili, Departamento de Endocrinología, Cra 98 No. 18-49, Cali 760032, ColombiaUniversidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, Colombia; Fundación Valle del Lili, Departamento de Endocrinología, Cra 98 No. 18-49, Cali 760032, ColombiaUniversidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, Colombia; Fundación Valle del Lili, Departamento de Endocrinología, Cra 98 No. 18-49, Cali 760032, ColombiaFundación Valle del Lili, Centro de Investigaciones Clínicas, Cra 98 No. 18-49, Cali 760032, Colombia; Corresponding author.Universidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, Colombia; Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cra 98 No. 18-49, Cali 760032, ColombiaFundación Valle del Lili, Departamento de Endocrinología, Cra 98 No. 18-49, Cali 760032, ColombiaUniversidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, ColombiaIntroduction: Insulin pumps serve as alternative insulin delivery methods with physiological similarity to the normal pancreas. The MiniMed 780G device is an advanced closed-loop hybrid system. Recent real-life studies have allowed reaching a higher percentage of time in range (TIR) (70 to 180 mg/dL). Being an emerging technology, it is of the utmost value to report on the early experience of use of this device. Methods: This was an observational, descriptive, cross-sectional study that included patients older than 18 years with types 1 diabetes mellitus and other types switched to a Medtronic 780G insulin pump. Baseline clinical and glycemic control variables and those after 4 weeks of using the SmartGuard mode were evaluated. Results: Thirty-nine patients (mean age, 33 years) were analyzed, 95 % of whom had type 1 diabetes with an average disease duration of 17 years. The values for time below range (TBR) <54 mg/dL, TBR <70 mg/dL, TIR, time above range (TAR) >180 mg/dL, and TAR >250 mg/dL were 0 %, 3 %, 72 %, 21 %, and 3 %, respectively, at baseline and 1 %, 2 %, 79 %, 14 %, and 2 %, respectively, after the intervention. The changes in TIR varied based on prior therapy: multiple daily injections of insulin, 13 % improvement; MiniMed Paradigm Veo/MiniMed 640G, 6 % improvement; and MiniMed 670G, −4 % improvement. Conclusion: In conclusion, the application of a hybrid closed-loop system allowed for better glycemic control based on international standards. The average percentage improvement in TIR was lower than that in other studies and was dependent on the previous method of insulin administration, achieving lower performance with the migration from recent technologies such as the Minimed 670G.http://www.sciencedirect.com/science/article/pii/S266639612300016XClosed-loop hybrid systemTime in rangeContinuous glucose monitoringInsulin infusion pumpGlycemic control |
| spellingShingle | Guillermo Edinson Guzmán-Gómez Karen Milena Feriz-Bonelo Víctor Manuel Blanco-Pico María Angelica Guerra Oriana Arias-Valderrama Valentina Marin-Betancourth Andrés Octavio García-Trujillo Switching to a Minimed 780G closed-loop hybrid system: Real-life experience in a center of Latin America Endocrine and Metabolic Science Closed-loop hybrid system Time in range Continuous glucose monitoring Insulin infusion pump Glycemic control |
| title | Switching to a Minimed 780G closed-loop hybrid system: Real-life experience in a center of Latin America |
| title_full | Switching to a Minimed 780G closed-loop hybrid system: Real-life experience in a center of Latin America |
| title_fullStr | Switching to a Minimed 780G closed-loop hybrid system: Real-life experience in a center of Latin America |
| title_full_unstemmed | Switching to a Minimed 780G closed-loop hybrid system: Real-life experience in a center of Latin America |
| title_short | Switching to a Minimed 780G closed-loop hybrid system: Real-life experience in a center of Latin America |
| title_sort | switching to a minimed 780g closed loop hybrid system real life experience in a center of latin america |
| topic | Closed-loop hybrid system Time in range Continuous glucose monitoring Insulin infusion pump Glycemic control |
| url | http://www.sciencedirect.com/science/article/pii/S266639612300016X |
| work_keys_str_mv | AT guillermoedinsonguzmangomez switchingtoaminimed780gclosedloophybridsystemreallifeexperienceinacenteroflatinamerica AT karenmilenaferizbonelo switchingtoaminimed780gclosedloophybridsystemreallifeexperienceinacenteroflatinamerica AT victormanuelblancopico switchingtoaminimed780gclosedloophybridsystemreallifeexperienceinacenteroflatinamerica AT mariaangelicaguerra switchingtoaminimed780gclosedloophybridsystemreallifeexperienceinacenteroflatinamerica AT orianaariasvalderrama switchingtoaminimed780gclosedloophybridsystemreallifeexperienceinacenteroflatinamerica AT valentinamarinbetancourth switchingtoaminimed780gclosedloophybridsystemreallifeexperienceinacenteroflatinamerica AT andresoctaviogarciatrujillo switchingtoaminimed780gclosedloophybridsystemreallifeexperienceinacenteroflatinamerica |